Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12056410 | 0.85 | — | — | |
| SCHEMBL12353678 | 0.79 | NPC1 (0.35) | SPHK2SPHK1 | |
| SCHEMBL11858528 | 0.79 | SPHK1 (0.42) | SPHK2SPHK1HSD17B10 | |
| SCHEMBL3962044 | 0.79 | SPHK1 (0.38) | SPHK2SPHK1HSD17B10 | |
| SCHEMBL12555004 | 0.77 | TSHR (0.34) | SPHK2SPHK1HSD17B10 | |
| SCHEMBL31086433 | 0.76 | SPHK1 (0.44) | SPHK2SPHK1HSD17B10 | |
| SCHEMBL10119365 | 0.76 | SPHK1 (0.44) | SPHK2SPHK1HSD17B10 | |
| SCHEMBL20127153 | 0.76 | SPHK2 (0.33) | SPHK2SPHK1 | |
| SCHEMBL10036614 | 0.74 | CYP3A4 (0.34) | SPHK2SPHK1 | |
| SCHEMBL723497 | 0.73 | HSD17B10 (0.41) | SPHK2SPHK1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110062165-A1 | BALANCED INDIVIDUAL DINING PLATE | ALLERGAN INC | 2011-03-17 | — | — | US | disclosed |
| US-20090215740-A1 | THERAPEUTIC SUBSTITUTED BETA-LACTAMS | ALLERGAN, INC. (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215740-A1 | THERAPEUTIC SUBSTITUTED BETA-LACTAMS | TUBB, GANAB, TUBB6 | SPHK2 3369/4885SPHK1 3150/4885HSD17B10 2446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.